Article
Clinical sequencing identifies potential actionable alterations in a high rate of urachal and primary bladder adenocarcinomas.
Cancer medicine - 1 Apr 2023
Varadi Melinda, Nagy Nikolett, Reis Henning, Hadaschik Boris, Niedworok Christian, Modos Orsolya, Szendroi Attila, Ablat Jason, Black Peter C, Keresztes David, Csizmarik Anita, Olah Csilla, Gaisa Nadine T, Kiss Andras, Timar Jozsef, Toth Erika, Csernak Erzsebet, Gerstner Arpad, Mittal Vinay, Karkampouna Sofia, Kruithof de Julio Marianna, Gyorffy Balazs, Bedics Gabor, Rink Michael, Fisch Margit, Nyirady Peter, Szarvas Tibor
Abstract excerpt
OBJECTIVE: Administration of targeted therapies provides a promising treatment strategy for urachal adenocarcinoma (UrC) or primary bladder adenocarcinoma (PBAC); however, the selection of appropriate drugs remains difficult. Here, we aimed to establish a routine compatible methodological pipeline for the identification of the most important therapeutic targets and potentially effective drugs for UrC and PBAC....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.